Manufacturing news briefs — stories you might have missed
Mesoblast secures FDA approval for heart disease treatment Biotechnology company Mesoblast has secured US Food and Drug Administration (FDA) approval for its Revascor heart disease treatment. The FDA issued a rare pediatric disease (RPD) designation for Revascor following submission of results from a trial in 19 children with hypoplastic left heart syndrome (HLHS). Revascor is…
